Cross-Resistance among Nonnucleoside Reverse Transcriptase Inhibitors Limits Recycling Efavirenz after Nevirapine Failure
- 20 August 2002
- journal article
- research article
- Published by Mary Ann Liebert Inc in AIDS Research and Human Retroviruses
- Vol. 18 (12), 835-838
- https://doi.org/10.1089/08892220260190308
Abstract
Heterogeneity in genotype mutations associated with resistance of HIV to nonnucleoside reverse transcriptase inhibitors (NNRTIs) should allow identification of patients failing nevirapine (NVP) who might benefit from efavirenz (EFV)-containing salvage regimens. To establish the feasibility of recycling EFV after failure of NVP-containing regimens genotypic data on 103 NVP-failed patients were analyzed to evaluate the prevalence of EFV resistance-conferring mutations. A clinically significant resistance to EFV was found in 50 of 103 (58%) of NVP-failed subjects. Furthermore, the 3-month virological response to salvage regimens containing EFV was assessed in patients previously treated with NVP and carrying single mutations conferring resistance to this drug. A proportion of HIV RNA less than 500 copies/ml at 3 months was obtained only in 2 of 12 (17%) of EFV-treated subjects compared with 35 of 67 (52%) of those without NNRTI mutations (OR, 0.18; 95% CI, 0.03-0.79). The median HIV-1 RNA decrease after 3 months was -0.63 log10 among patients carrying single NNRTI-associated mutations compared with -1.32 log10 among those without any NNRTI mutations. No virological response was observed in six patients harboring a single Y181C/I mutation. On the basis of the present data, sequential use of NNRTIs should be avoided in the management of treatment failure.Keywords
This publication has 9 references indexed in Scilit:
- Nonnucleoside Reverse Transcriptase Inhibitor ResistanceJAIDS Journal of Acquired Immune Deficiency Syndromes, 2001
- Clinical Use of Genotypic and Phenotypic Drug Resistance Testing to Monitor Antiretroviral ChemotherapyClinical Infectious Diseases, 2001
- Incomplete Genotypic Resistance to Nonnucleoside Reverse Transcriptase Inhibitors in Patients Treated With Nevirapine: A Potential Interest in Clinical PracticeJAIDS Journal of Acquired Immune Deficiency Syndromes, 2000
- Human Immunodeficiency Virus Type 1 Mutations Selected in Patients Failing Efavirenz Combination TherapyAntimicrobial Agents and Chemotherapy, 2000
- Rapid Communication: Efavirenz- and Adefovir Dipivoxil–Based Salvage Therapy in Highly Treatment-Experienced Patients: Clinical and Genotypic Predictors of Virologic ResponseJAIDS Journal of Acquired Immune Deficiency Syndromes, 2000
- Patterns of Resistance Mutations Selected by Treatment of Human Immunodeficiency Virus Type 1 Infection with Zidovudine, Didanosine, and NevirapineThe Journal of Infectious Diseases, 2000
- Non-nucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimenAIDS, 2000
- Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapyJournal of Virology, 1994